The invention relates to a sequence of hepatitis c virus (HCV) cell-entrance-inhibiting peptides ZTE1 and an application. The peptides are synthesized on the basis of an amino acid sequence of an envelope protein E2 of an HCV genotype 2A reference strain JFH-1 (GenBank no.D95A86), wherein a purity of the peptides is more than 85%. Each peptide is composed of 15 amino acids (aa). Each two adjacent peptides have 10 overlapped amino acids. In the invention, two adjacent peptides, E2-42 and E2-43, which have amino acid sequences represented as the Seq ID:No.1 and the Seq ID:No.2 and are respectively located at the positions of 548aa-562aa and 552aa-566aa in a JFH-1E2 amino acid sequence. The 10 overlapped amino acids are named ZTE1 of which a sequence is represented as the Seq ID:No.3. Under a condition of a peptide usage amount being 5 nM, the two peptides can reach an HCV infection-inhibiting rate of 50%. In an experiment for researching an infection-inhibiting mechanism of the peptides, a result proves that when the peptides (10 nM) and the virus both exist, the peptides can effectively inhibit virus infection with an inhibiting ratio reaching about 90%. The experiment proves that the two peptides obtained in the invention works in a manner of a biological process of preventing the virus from entering cells.